https://www.prnewswire.com/il/news-releases/compugen-reports-third-quarter-2024-results-302302282.html
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in...
third quartercompugenreportsresults
https://www.prnewswire.com/news-releases/compugen-reports-third-quarter-2024-results-302302282.html
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in...
third quartercompugenreportsresults
https://www.prnewswire.com/news-releases/compugen-added-to-the-nasdaq-biotechnology-index-300978219.html
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that...
nasdaq biotechnology indexcompugenadded
https://www.prnewswire.com/news-releases/compugen-to-present-data-update-on-com701-phase-1-clinical-trial-at-the-american-society-of-clinical-oncology-2021-annual-meeting-301279857.html
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that...
compugenpresentdataupdatephase
https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-metastatic-breast-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-259451&utm_campaign=recommended-articles-pi
COM-701 is under clinical development by Compugen and currently in Phase I for Metastatic Breast Cancer.
metastatic breast cancercomlikelihood
https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-hypopharyngeal-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-349851&utm_campaign=recommended-articles-pi
COM-701 is under clinical development by Compugen and currently in Phase II for Hypopharyngeal Cancer.
hypopharyngeal cancercomlikelihoodapproval
https://www.trendmicro.com/en/partners/partner-stories/compugen.html
Gains greater visibility, detection, and response with Trend Vision One XDR capabilities
trend microcompugen